• For inclusion in neoadjuvant therapy, patients should fulfil the following criteria:

‣ Provision of signed, written and dated informed consent prior to any study specific procedures;

⁃ Male or female aged 18\

∙ 75 years old;

⁃ Patients must have histologically- or cytologically-documented NSCLC who present with locally advanced (Stage III) disease;

⁃ Without prior chemotherapy, radiotherapy, surgery, targeted therapy or immunotherapy;

⁃ A recent tumour biopsy (taken following completion of the most recent therapy) is an optional requirement, provided that a biopsy procedure is technically feasible and the procedure is not associated with unacceptable clinical risk;

⁃ Life expectancy ≥12 weeks;

⁃ World Health Organization (WHO) Performance Status of 0 or 1;

⁃ Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients within 14 days before the use of study drug (HCG has a minimum sensitivity of 25 IU/L or equivalent);

⁃ Women must be non-breastfeeding

⁃ Forced expiratory volume in 1 second (FEV1) ≥800ml

⁃ Absolute neutrophil count \>1.5 x 109/L (1500 per mm3)

⁃ Platelets \>100 x 109/L (100,000 per mm3)

⁃ Haemoglobin≥9.0 g/dL (5.59 mmol/L)

⁃ Serum creatinine clearance(CL) \>50 mL/min by the Cockcroft-Gault formula (Cockcroft and -Gault 1976)

⁃ Serum bilirubin ≤1.5 x upper limit of normal (ULN). Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤2.5 x ULN